key: cord-0060719-ry3ap0ss authors: Strizich, Lindee M.; Choe, John H. title: Management of Pneumonia date: 2020-10-01 journal: Chalk Talks in Internal Medicine DOI: 10.1007/978-3-030-34814-4_30 sha: f0057d7dbf0e5acebf66cd5de495403e13e83a87 doc_id: 60719 cord_uid: ry3ap0ss Community-acquired pneumonia is one of the most common diagnoses encountered in medicine. However, pneumonia encompasses a broad range of severity and causative agents necessitating different treatments, often based on patient-specific factors rather than available culture results. Choosing the most appropriate treatments and management strategies depends on a strong understanding of the risk factors associated with various pathogens. • Several tools are available to risk-stratify the patient and aid in management decisions. • Commonly used tools include the PSI/PORT score, which includes age, sex, nursing home residency, medical comorbidities, vital sign abnormalities, laboratory data, and imaging findings. • The CURB-65 score is easy to remember (confusion, BUN > 20, RR > 30, SBP < 90 or DBP < 60, and age >65)-hospital admission should be considered for anyone with two or more features. • Low-risk patients (those who are less sick), such as our patient, can be treated an outpatient. Teaching points • Consult local antibiotic susceptibility and practice patterns for specific antibiotic recommendations-general guidelines are given here. • Beta-lactam (amoxicillin or amox/clav) +/-a macrolide or doxycycline, oseltamivir if concerned for influenza (note that adding oseltamivir is true for all the categories of pneumonia and treatment settings discussed). G. What if our patient's labs came back with a creatinine of 2, BUN of 40, and was requiring 2 L nasal cannula oxygen to maintain his oxygen saturation at 95%, had a respiratory rate of 20, was tachycardic to 105, and his BP was 127/78? Teaching points • Higher risk patients (i.e., those who are more sick) should be admitted and further stratified to floor or ICU level care based on hemodynamic stability. • This patient sounds stable for the acute care floor-macrolide and beta-lactam are preferred, may consider fluoroquinolone. H. As we are putting in admission orders, we hear that our patient is now requiring 8 L nasal cannula oxygen to maintain his oxygen saturation at 95%, his respiratory rate has increased to 32, his heart rate is now 127, and his blood pressure is now 95/60. Where does this patient get admitted to the hospital and what antibiotics would you choose? Teaching points • This patient should be admitted to the ICU but the antibiotic recommendations are the same as for floor patients, unless there is concern for MRSA or Pseudomonas spp. • Severity scores ➔ treatment in either outpatient or inpatient setting with inpatient further stratified to acute care floor vs. ICU Refer back to the most common organisms learners should be concerned about for each type of pneumonia • Must take into account exposures and patient characteristics • Remind learners that their antibiotic selection should cover the organisms that they are concerned for, taking into account local antibiotic susceptibilities Clinical practice. Community-acquired pneumonia Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Community-acquired pneumonia Diagnosis and management of community-acquired pneumonia in adults Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Recognition and prevention of nosocomial pneumonia in the intensive care unit and infection control in mechanical ventilation Nosocomial pneumonia: lessons learned Ventilator associated pneumonia VAP Guidelines Committee and the Canadian Critical Care Trials Group. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention